This site is intended for healthcare professionals

New data for Tecartus demonstrates durable responses at one year in ZUMA-2 trial follow-up in relapsed or refractory mantle cell lymphoma- Kite/Gilead

Read time: 1 mins
Last updated:6th Dec 2020
Published:6th Dec 2020
Condition: Mantle Cell Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest